Breaking News

Meritage Homes Banks On Entry-Level Buyers, Lower ASP Hurts

By Zacks Investment ResearchStock MarketsAug 14, 2019 10:51PM ET
Meritage Homes Banks On Entry-Level Buyers, Lower ASP Hurts
By Zacks Investment Research   |  Aug 14, 2019 10:51PM ET
Saved. See Saved Items.
This article has already been saved in your Saved Items

Meritage Homes Corporation (NYSE:MTH) is poised to benefit from its focus on building single-family homes for entry-level and first-time homebuyers. Notably, the company is particularly focused on increasing gross margin and maximizing profits on every sale.

However, rising cost of labor and land are concerning. Also, lower average sales price or ASP is hurting its margins.

A Look at Meritage Homes’ Q2 Performance

Last month, the company reported second-quarter 2019 results, wherein earnings and revenues surpassed the respective Zacks Consensus Estimate, buoyed by strong homebuying activity. Earnings of $1.31 per share topped the consensus mark of $1.03 by 27.2%. The reported figure was in line with the year-ago profit level. Lower home closing revenues and increased interest and SG&A expenses were offset by higher gross margin.

Quarterly order volume (up 21.6% year over year) marked a 13-year record high, driven by a 19% improvement in absorption pace and marginal increase in average community count.

Let’s delve deeper into the factors that are supporting the company’s performance.

Major Growth Drivers

Focus on First-Time/Entry-Level Buyers Bodes Well: Meritage Homes remains focused on boosting demand for entry-level homes with the LiVE.NOW product that addresses the need for lower-priced homes, given affordability concerns. The successful execution of strategic initiatives to boost profitability and focus on entry-level LiVE.NOW homes bode well. Meritage Homes is continuously building homes on a spec basis for LiVE.NOW. communities.

The company believes that the strategy of targeting entry-level buyers is gaining traction and will continue to boost its performance over the long haul. In second-quarter 2019, 41% of total communities and 52% of orders were entry level compared with 34% and 44%, respectively, in the year-ago period.

Upbeat View: The company remains optimistic about second-half 2019 results on the back of an improving demand trend for homes and communities, along with lower interest rates.

Meritage Homes now expects full-year 2019 home closings in the range of 8,700-9,100 versus 8,200-8,700 projected earlier. The mid-point of the guided range is higher than the year-ago reported figure of 8,531 homes. The company expects total home closing revenues within $3.4-$3.6 billion versus $3.25-3.45 billion expected earlier. In 2018, it reported home closing revenues of $3.47 billion.

The company anticipates home closing gross margin in mid-18% and earnings within $5.20-$5.50 per share compared with $4.65-4.95 expected earlier.


The company’s home closing revenues dropped 1.1% in second-quarter 2019 due to 6% reduced average selling price or ASP, offsetting 5.3% volume growth. Meritage Homes has reduced the average selling price or ASP for homes in order to address the needs of millennials and baby boomers who want affordable homes, and highly desirable communities.

Meanwhile, the company has been experiencing higher SG&A expenses, mainly due to higher brokerage commissions. Total SG&A was 11.6% of 2019 home closing revenues in first-half 2019 compared with 11.2% in the same period of 2018.

Meanwhile, rising labor and land costs are pressing concerns for Meritage Homes, and other homebuilding companies like KB Home (NYSE:KBH) , M.D.C. Holdings, Inc. (NYSE:MDC) , PulteGroup, Inc. (NYSE:PHM) , Lennar Corporation (NYSE:LEN) and others.

Breakout Biotech Stocks with Triple-Digit Profit Potential

The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.

Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +98%, +119% and +164% in as little as 1 month. The stocks in this report could perform even better.

See these 7 breakthrough stocks now>>

KB Home (KBH): Free Stock Analysis Report

Meritage Corporation (MTH): Free Stock Analysis Report

M.D.C. Holdings, Inc. (MDC): Free Stock Analysis Report

PulteGroup, Inc. (PHM): Free Stock Analysis Report

Lennar Corporation (LEN): Free Stock Analysis Report

Original post

Zacks Investment Research
Meritage Homes Banks On Entry-Level Buyers, Lower ASP Hurts
Meritage Homes Banks On Entry-Level Buyers, Lower ASP Hurts

Add a Comment

Comment Guidelines

We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind: 

  • Enrich the conversation
  • Stay focused and on track. Only post material that’s relevant to the topic being discussed.
  • Be respectful. Even negative opinions can be framed positively and diplomatically.
  •  Use standard writing style. Include punctuation and upper and lower cases.
  • NOTE: Spam and/or promotional messages and links within a comment will be removed
  • Avoid profanity, slander or personal attacks directed at an author or another user.
  • Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at’s discretion.

Write your thoughts here
Are you sure you want to delete this chart?
Post also to:
Replace the attached chart with a new chart ?
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
Are you sure you want to delete this chart?
Replace the attached chart with a new chart ?
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn`t bear any responsibility for any trading losses you might incur as a result of using this data.

Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.
Continue with Google
Sign up with Email